UBS Raises Merck (MRK) Price Forecast as Part of Sector Preview

Merck & Co., Inc. (NYSE:MRK) is included among the 10 Healthcare Stocks with Highest Dividends.

UBS Raises Merck (MRK) Price Forecast as Part of Sector Preview

On April 13, UBS analyst Michael Yee lifted the firm’s price recommendation on Merck & Co., Inc. (NYSE:MRK) to $145 from $130. It reiterated a Buy rating on the shares. The revision was part of a broader Q1 preview across the pharmaceuticals and biotechnology group.

A few days earlier, on April 7, the company said it would begin a cash tender offer, through a subsidiary, to acquire all outstanding shares of common stock of Terns Pharmaceuticals. This followed an earlier move on March 25, 2026, when Merck entered into a definitive agreement to acquire Terns.

If the offer closes as expected, Terns stockholders will receive $53.00 net in cash for each share that is validly tendered and not withdrawn. The payment will not include interest and will be subject to any applicable tax withholding. After the shares are purchased through the tender offer, Terns will become a wholly owned subsidiary of Merck.

Merck & Co., Inc. (NYSE:MRK) is a global healthcare company focused on delivering health solutions through its prescription medicines. Its portfolio includes biologic therapies, vaccines, and animal health products. The Pharmaceutical segment covers its human health pharmaceutical and vaccine business.

While we acknowledge the risk and potential of MRK as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than MRK and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 14 Value Stocks with Highest Dividends and Early Retirement Portfolio: Top 15 Stocks to Buy

Disclosure: None. Follow Insider Monkey on Google News.